Scott Matusow

Antares Pharma's New Blockbuster Drug Has Potential To Generate Long-Term Revenue	Antares Pharma: Insiders And Institutions Appear Bullish	These 2 Bio-Pharmas Could Be High Flyers In 2012
WebMD Hammered On Latest News	Ariad: This Bio-Pharma May Deliver Big Returns	Seadrill Limited: $3 A Share Dividend
SIGA Could Be Ready For A Large Short-Term Pop	Questcor: A Mid Cap Bio-Pharma With Bullish Indicators	Molycorp: Don't Buy Into The Hype
A Bio-Pharma Buy And Sell List: Part 2	A Bio-Pharma Buy And Sell List: Part 1	These Stocks Might Be Good Swing Trades
Stock Boards: Weeding Through The Nonsense, Getting To The Facts	Spectrum Pharma: Solid Tech, Solid Fundamentals, Explosive Growth	Vertex Pharmaceuticals Could See Huge Long-Term Gains
Movers And Shakers In This Week's Market	Antares's New RA Treatment Method Has Large Market Potential	GlaxoSmithKline Poised To Break 52-Week High
The Curious Case Of MannKind Corporation	Vertex Pharma's Latest FDA Approval Is Only The Beginning	Easing The Pain: Why Investment In Bio-Pharma Is A Worthy Cause
The Birth Control Pill Fiasco: Will It Be Bad For Pfizer?	BioLineRx: Strong Speculation Bio-Pharma, Strong Acquisition Target	Short Term Swing Trades 2 Week Report Card, With Deeper Analysis

Main menu